Umass Memorial Medical Center

The trials here

What the 40 trials at this site are about, from their registry records.

Conditions

• Stroke8 trials
• Cystic fibrosis3 trials
• Colorectal cancer2 trials
• Crohn's disease2 trials
• Diffuse large B-cell lymphoma2 trials
• Duchenne muscular dystrophy2 trials
• Epilepsy2 trials
• Liver and biliary tract cancer2 trials
• Obesity2 trials
• Pancreatic cancer2 trials
• Atrial fibrillation1 trial
• Bladder cancer1 trial
• and 14 more

Phase

• Phase 321 trials
• Phase 13 trials
• Phase 23 trials
• Phase 1/22 trials
• Phase 42 trials
• Phase 2/31 trial

Status

• Active, not recruiting15 trials
• Completed14 trials
• Recruiting6 trials
• Terminated3 trials
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Vertex Pharmaceuticals Incorporated3 trials
• Boehringer Ingelheim2 trials
• Joseph Broderick, MD2 trials
• Novartis Pharmaceuticals2 trials
• Rhythm Pharmaceuticals, Inc.2 trials
• and 27 more

Running trials

• Not yet recruiting

  The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease

  NCT07907991· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

  NCT07287189· Phase 2· Satellos Bioscience, Inc.· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

  Contact: Xavier Vela Parada (principal investigator)

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Joseph Broderick, MD· Source

  Contact: Adalia H. Jun-O'Connell, MD

• Recruiting

  A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

  NCT06909214· Phase 4· argenx· Source

  Contact: Shivkumar Bhadola, MD

• Active, not recruiting

  Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

  NCT05948475· Phase 3· TransThera Sciences (Nanjing), Inc.· Source

• Active, not recruiting

  Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis:

  NCT05505552· Tufts University· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

  NCT05653219· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

  NCT05524883· Phase 1/2· Dyne Therapeutics· Source

• Active, not recruiting

  Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

  NCT05047172· Phase 3· University of Florida· Source

• Active, not recruiting

  RADIANCE Continued Access Protocol

  NCT05017935· ReCor Medical, Inc.· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

  NCT05164094· Phase 1/2· ModernaTX, Inc.· Source

• Active, not recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

  NCT03496883· Phase 3· Joseph Broderick, MD· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

  NCT04956744· Phase 1· ImStem Biotechnology· Source

• Recruiting

  Pancreatic Cancer Early Detection Consortium

  NCT04970056· Arbor Research Collaborative for Health· Source

  Contact: Paige Malone

• Active, not recruiting

  Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

  NCT04498117· Phase 3· CanariaBio Inc.· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

  Contact: Majaz Moonis, MD

• Active, not recruiting

  A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

  NCT04194775· Phase 3· CStone Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke2 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• COPD1 recruiting
• IgA nephropathy1 recruiting
• Myasthenia gravis1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Completed

  SafeHeal Diverting Ileostomy Pivotal Study

  NCT06152276· SafeHeal Inc· Source

• Terminated

  NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

  NCT05664217· Phase 2/3· Nektar Therapeutics· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Xenon Pharmaceuticals Inc.· Source

  Contact: Xenon Medical Affairs

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

  NCT05364424· Phase 1· Hoffmann-La Roche· Source

• Completed

  THUNDER: Acute Ischemic Stroke Study With the Penumbra System® Including Thunderbolt™ Aspiration Tubing

  NCT05437055· Penumbra Inc.· Source

• Completed

  EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

  NCT05093634· Phase 3· Rhythm Pharmaceuticals, Inc.· Source

• Terminated

  SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

  NCT05010850· SafeHeal Inc· Source

• Completed

  Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing

  NCT04741009· Cochlear· Source

• Completed

  DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

  NCT04963231· Phase 2· Rhythm Pharmaceuticals, Inc.· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

  NCT04809363· Phase 4· Takeda· Source

• Completed

  Multi-arm Optimization of Stroke Thrombolysis

  NCT03735979· Phase 3· Washington University School of Medicine· Source

• Completed

  Sleep for Stroke Management and Recovery Trial

  NCT03812653· University of Michigan· Source

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

  NCT03893682· Phase 1· Aptose Biosciences Inc.· Source

• Completed

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· Phase 3· NovoCure Ltd.· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source